Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,359 stopped studies mapped to Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,359 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02092909 | Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's…(8400-401) | Phase 1 / Phase 2 | terminated | Mar 20, 2014 | Idera Pharmaceuticals, Inc. | Lack of efficacy | Efficacy / futility |
| NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | Phase 2 | terminated | Jan 13, 2006 | Masonic Cancer Center, University of Minnesota | Drug was not available. | Other (stated, no rule matched) |
| NCT02614508 | Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Nov 25, 2015 | Emory University | not stated | Not stated |
| NCT01738594 | Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell… | Phase 1 | terminated | Nov 30, 2012 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT01090414 | An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101;… | Phase 1 / Phase 2 | terminated | Mar 22, 2010 | Gilead Sciences | not stated | Not stated |
| NCT03785184 | A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly… | Phase 2 | withdrawn | Dec 24, 2018 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT03232307 | Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly… | Phase 2 | withdrawn | Jul 27, 2017 | M.D. Anderson Cancer Center | Sponsor does not wish to proceed | Other (stated, no rule matched) |
| NCT00089284 | Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL | Phase 1 / Phase 2 | terminated | Aug 5, 2004 | Northwestern University | Due to lack of funding, phase II of study was not completed. | Funding |
| NCT03657420 | Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and… | Phase 1 | withdrawn | Sep 5, 2018 | Massachusetts General Hospital | Funding withdrawn by sponsor | Funding |
| NCT02535806 | Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children… | Phase 2 | terminated | Aug 31, 2015 | Children's Mercy Hospital Kansas City | Funding source discontinued | Funding |
| NCT02954796 | A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma | Phase 1 | terminated | Nov 3, 2016 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT00167180 | Post Transplant Donor Lymphocyte Infusion | Phase 2 | terminated | Sep 14, 2005 | Masonic Cancer Center, University of Minnesota | Accrual Goal Met | Enrollment / accrual |
| NCT02360111 | GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal… | N/A | terminated | Feb 10, 2015 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT03074825 | Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma | Phase 1 | terminated | Mar 9, 2017 | Chipscreen Biosciences, Ltd. | The results fell short of expectations. | Other (stated, no rule matched) |
| NCT03393273 | Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell…(IFM2016-03) | Phase 2 | withdrawn | Jan 8, 2018 | Assistance Publique - Hôpitaux de Paris | Investigator decision in accordance with the promotor | Investigator |
| NCT01875237 | Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | Phase 1 / Phase 2 | terminated | Jun 11, 2013 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01111188 | Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma | Phase 1 | terminated | Apr 27, 2010 | Weill Medical College of Cornell University | not stated | Not stated |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT02106091 | Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive… | Phase 1 | terminated | Apr 8, 2014 | Affimed GmbH | Non-favorable risk/benefit profile with studied dosing regimen | Other (stated, no rule matched) |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT03333746 | Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple… | Phase 2 | terminated | Nov 7, 2017 | Yvonne Efebera | Study was discontinued due to FDA recommendations of the potential toxicities of the combination of… | Safety / toxicity |
| NCT02592876 | Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for… | Phase 2 | terminated | Oct 30, 2015 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT02907073 | Positron Emission Tomography (PET) Imaging Studies With NIS Reporter | Phase 1 / Phase 2 | terminated | Sep 20, 2016 | Mayo Clinic | pursuing IND | Other (stated, no rule matched) |
| NCT02613182 | Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis(OLE) | Phase 2 | terminated | Nov 24, 2015 | Prothena Biosciences Ltd. | NEOD001 program terminated due to lack of clinical benefit | Efficacy / futility |
| NCT02258529 | Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and… | Phase 2 | terminated | Oct 7, 2014 | Gilead Sciences | not stated | Not stated |
| NCT03373305 | Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory… | Phase 1 | withdrawn | Dec 14, 2017 | City of Hope Medical Center | contract not executed | Other (stated, no rule matched) |
| NCT01927718 | Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell… | N/A | terminated | Aug 23, 2013 | M.D. Anderson Cancer Center | Poor Response Rate | Other (stated, no rule matched) |
| NCT03558750 | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or… | Phase 1 | terminated | Jun 15, 2018 | Vanderbilt-Ingram Cancer Center | Low accrual | Enrollment / accrual |
| NCT02568683 | Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in… | Phase 1 / Phase 2 | terminated | Oct 6, 2015 | Gilead Sciences | not stated | Not stated |
| NCT01287741 | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP… | Phase 3 | terminated | Feb 1, 2011 | Hoffmann-La Roche | The study was closed by the Sponsor according to the protocol-specified minimum post-treatment… | Other (stated, no rule matched) |
| NCT02518750 | Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or… | Phase 2 | terminated | Aug 10, 2015 | St. Jude Children's Research Hospital | Due to slow accrual | Enrollment / accrual |
| NCT02900248 | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing…(N1) | — | terminated | Sep 14, 2016 | CureOne | Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data. | Other (stated, no rule matched) |
| NCT03154047 | Study in Subjects With Light Chain (AL) Amyloidosis | Phase 2 | terminated | May 15, 2017 | Prothena Biosciences Ltd. | NEOD001 program terminated due to lack of clinical benefit | Efficacy / futility |
| NCT03856112 | Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With… | Phase 1 / Phase 2 | withdrawn | Feb 27, 2019 | National Cancer Institute (NCI) | Per CTEP, Martha Khrum this study is withdrawn. Changing status to update CT.gov | Other (stated, no rule matched) |
| NCT03221634 | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in… | Phase 2 | withdrawn | Jul 18, 2017 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT01370694 | Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) | Phase 1 | terminated | Jun 10, 2011 | Merck Sharp & Dohme LLC | The study was terminated for business reasons. | Sponsor / business decision |
| NCT01948180 | Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma(CITADEL) | Phase 2 | terminated | Sep 23, 2013 | Cell Medica Ltd | Insufficient enrollment rate | Enrollment / accrual |
| NCT02855359 | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in… | Phase 2 | terminated | Aug 4, 2016 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | Phase 1 / Phase 2 | terminated | Apr 1, 2008 | Alexion Pharmaceuticals, Inc. | The study was terminated by the Sponsor for administrative reasons and not due to any safety… | Safety / toxicity |
| NCT00920556 | A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With… | Phase 2 | terminated | Jun 15, 2009 | Sirtris, a GSK Company | Study terminated.24 subjects enrolled;provided adequate data for decision making. | Enrollment / accrual |
| NCT03379493 | Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma | Phase 1 | terminated | Dec 20, 2017 | Eureka Therapeutics Inc. | Sponsor's Decision | Sponsor / business decision |
| NCT03168100 | 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule… | Phase 2 | withdrawn | May 30, 2017 | University of Arkansas | No study population. No subjects enrolled. | Enrollment / accrual |
| NCT02145598 | Treatment Optimization in Patients With Untreated Multiple Myeloma(GERMAIN) | Phase 2 / Phase 3 | terminated | May 23, 2014 | Dr. med. Lars-Olof Muegge | Insufficient recruitment | Enrollment / accrual |
| NCT03132584 | Cyclophosphamide and Alemtuzumab In Lymphoma | Phase 1 | terminated | Apr 28, 2017 | Dana-Farber Cancer Institute | slow accrual | Enrollment / accrual |
| NCT03218163 | MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma | Phase 2 | terminated | Jul 14, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | MEDI-551 removed from oncology by pharmaceutical company due to change in research target. | Sponsor / business decision |
| NCT01892293 | CT Antigen TCR-Engineered T Cells for Myeloma | Phase 1 / Phase 2 | terminated | Jul 4, 2013 | Adaptimmune | Sponsor Decision | Sponsor / business decision |
| NCT02657447 | Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02) | Phase 1 | withdrawn | Jan 15, 2016 | Nordic Nanovector | Study is no longer relevant | Other (stated, no rule matched) |
| NCT01232556 | A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive… | Phase 3 | terminated | Nov 2, 2010 | Pfizer | The study was terminated prematurely on May 16, 2013, for futility. No new or unexpected safety… | Safety / toxicity |
| NCT01303965 | Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple… | Phase 1 / Phase 2 | terminated | Feb 25, 2011 | Sherif S. Farag | Slow accrual | Enrollment / accrual |
| NCT02008006 | BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy…(BENEFIT) | Phase 2 | terminated | Dec 11, 2013 | Centre Leon Berard | Insufficient recruitment and unavailability of the treatment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 10, 2019source: clinicaltrials